WO2001038585A2 - Matrices polymeres et procedes d'utilisation de molecules de sondes marquees pour identifier et quantifier l'expression des molecules cibles - Google Patents

Matrices polymeres et procedes d'utilisation de molecules de sondes marquees pour identifier et quantifier l'expression des molecules cibles Download PDF

Info

Publication number
WO2001038585A2
WO2001038585A2 PCT/US2000/032303 US0032303W WO0138585A2 WO 2001038585 A2 WO2001038585 A2 WO 2001038585A2 US 0032303 W US0032303 W US 0032303W WO 0138585 A2 WO0138585 A2 WO 0138585A2
Authority
WO
WIPO (PCT)
Prior art keywords
probe molecules
labeled probe
substrate
molecules
target
Prior art date
Application number
PCT/US2000/032303
Other languages
English (en)
Other versions
WO2001038585A3 (fr
Inventor
Norbert Reich
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to AU18006/01A priority Critical patent/AU1800601A/en
Publication of WO2001038585A2 publication Critical patent/WO2001038585A2/fr
Publication of WO2001038585A3 publication Critical patent/WO2001038585A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Definitions

  • This invention relates generally to array based assays and more particularly to microarrays or beads having labeled probes molecules which are designed to assist in the identification and quantification of target molecules including native molecules or mutant molecules.
  • Microarray technology consists, generally, of probe molecules being attached to a solid substrate and target molecules, obtained from the exposed cells contacting the probe molecules.
  • target molecules are labeled prior to exposure to the microarray.
  • some target molecules selectively form probe target pairs by binding/hybridizing with the complimentary probe molecules on the microarray.
  • the target molecules that do not form pairs are removed from the microarray.
  • the scientist can then visualize the probe molecules which were bound by labeled target molecules.
  • the relative amount of probe/target pairs which form can be compared between groups of cells which are exposed to different treatments and cells which are O 01/38585
  • microarrays may be used to improve timeliness, effectiveness, accuracy and overall benefit-to-cost ratio for examining changes in molecular expression and function relative to traditional methods.
  • the target molecule is typically labeled, and that label is detected to identify the probe/target pair.
  • the label may not be present on the target molecule in sufficient amounts to be detectable. If a target sequence is not adequately labeled, false negative results are obtained, meaning that probe/target pairs are formed, but not identified by the scientist. Labeling inadequacies often occur due to enzymatic reproducibility, inhibition and or incomplete incorporation of dyes.
  • Labeled probe molecules where the label is detectable when the probe molecule is not paired with a complimentary target molecule, and the label is undetectable when paired with a target molecule. Such a system allows for a means of identifying target molecules in a sample without encountering the difficulty of labeling target molecules.
  • the probe and target molecules can be polymers of nucleic acids, amino acids or carbohydrates.
  • the label is preferably fluorescent, and can be detected by those methods currently known or to be developed in the art, such as flow cytometry.
  • the probe molecules can be attached to a solid substrate such as a microarray or a bead.
  • the probe molecules are single-stranded, fluorescently labeled nucleotide sequence which are attached to a microarray. The fluorescing nucleotide probe molecule is quenched when hybridized to a complimentary target nucleotide sequence.
  • the probe molecules are single-stranded, fluorescently labeled oligonucleotide sequences comprised in part or entirely by nucleotide base analogs.
  • a known number of labeled probe molecules are attached to a bead which can be contacted with the target sequences within a cellular sample.
  • the fluorescence of the probe molecule will be decreased.
  • a number of probe/target pairs are formed which is substantially equal to the number of probe molecules present on the bead, the fluorescence of the probe molecule will be substantially eliminated.
  • the beads can be used to quantify the amount of a target molecule in a cellular sample.
  • Figure 1 shows the known structures for native adenosine (1A); guanine and inosine_ via a generic structure (IB); cytidine (1C); and thymidine and uridine via a generic structure (ID).
  • the invention utilizes labeled probe molecules wherein the label is detectable when the probe molecule is not paired with a complimentary target molecule, and the label is undetectable when paired with a target molecule.
  • this invention allows for a means of identifying and quantifying a target molecule in a cellular sample without encountering the difficulty of labeling target molecules.
  • the probe and target molecules can be polymers of nucleic acids, amino acids or carbohydrates, and complimentary pairs may form due to hybridization, annealing, or binding, for example between any of a nucleic acid, amino acid or carbohydrate polymer.
  • the probe and target molecules can be synthesized or extracted from an organic source.
  • the molecules may be single stranded or double stranded.
  • the polymers may be comprised of native nucleotide bases (adenosine, guanine/inosine, cytidine or thymidine/uridine) or of nucleotide analogs, or any combination thereof.
  • the probe molecules can be comprised of a variety of different nucleotide analogues with preferred analogues having substantially the same or higher hybridization affinity for a target sequence as does a probe molecule comprised of native bases of the same length.
  • the probe molecules are comprised of nucleotide analogues which can substitute for a native nucleic acid bases in all or any of enzymatic reactions involving (1) nucleic acid replication; (2) ligation and (3) phosphorylation.
  • Nucleotide analogs including heterocyclic pyrimidine or purine structural analogs of naturally occurring bases which are fluorescent under physiological conditions may be used.
  • nucleotide analogues examples include, but are not limited to: 2 -amino purine at least for adenosine or guanine; ribonucleoside or 2,6-diamino ribonucleoside, formycin A, formycin B, oxyformycin B, toyocamycin, sangivamycin, pseudoouridine, showdomycin, minimycin, pyrazomycin, 5-amino-formycin A, 5-amino- formycin B or 5-oxo-fom ⁇ ycin A at least for adenosine; 4-amino-pyrazolo [3 reading 4d] pyrimidine, 4,6-diamino-pyrazolo [3 token 4d] pyrimidine, 4-amino-6-oxo-pyrazolo [3,, 4d] pyrimidine, 4-oxo- pyrazolo [3 tokenidine, 4-oxo-6-amino-6-amino
  • the probe molecule can be comprised of native nucleotide bases or nucleotide analogs, some of which or all of which are labeled.
  • some or all of the nucleotides are labeled with a fluorescing label.
  • only one base e.g. adenosine is substituted with an analogue (such as formycin, 2-amino purine, ribonucleoside or 2,6-diamino ribunucleoside), while the other nucleotides in the sequence are native.
  • analogue such as formycin, 2-amino purine, ribonucleoside or 2,6-diamino ribunucleoside
  • all the purines or alternatively all the pyrimidines are changed from the native nucleotide to a fluorescent nucleotide analog.
  • nucleic acid based probe molecule can be labeled after the probe molecule is produced. Detectable labels can be attached by a variety of known procedures. -Standard labeling protocols for amino acids and nucleic acids are described, for example in Sambrook et ⁇ /.(1989) Molecular Cloning: A Laboratory Manual, 2 nd Ed.
  • the fluorescing label is preferably 2-aminopurine, which fluoresces at a range of about 300 nm to about 700 nm, most preferably, the fluorescence is detectable by the unaided human eye.
  • the label may be fluorescent, and can be detected by those methods currently known or to be developed in the art, such as flow cytometry. Further, the label preferably fluoresces at a wavelength that is visible to an unaided human eye. Methodology utilizing 2-aminopurine as a labeled molecules is disclosed in Allen and Reich Biochemistry 1996, 35:1457-14762, herein incorporated in its entirety.
  • the probe molecules comprised of nucleotides can be produced using the known technology use to produce oligonucleotides, cDNA or RNA sequences.
  • the probe molecules using nucleotides may have a sugar-phosphate backbone which is identical to that of a native molecule. However, in some embodiments it can be desirable to provide a modified backbone to enhance nuclease resistance, for example, which can enhance the reusability of the microarrays. Techniques for modifying backbones are described in at least European Application EP 0 742 287 A2 to McGall, et al., incorporated herein by reference in its entirety.
  • the probes molecules comprised of nucleic acids can be of any desired length, but are preferably longer than four bases or analogs long, and most preferably about 6 to about 300 or more nucleotides.
  • probe molecules may also be amino acid based or carbohydrate based; such polymers can be synthesized and labeled according to methods of those presently known or to be developed by those skilled in the art, and those cited above.
  • Microarrays useful in this invention are any substrates which maximally facilitate the attachment of probe molecules thereto, and minimally interfere with probe/target pairing and further minimally interfere with detection of the label on the probe molecules.
  • the microarray has probe molecules of different molecules attached to its surface.
  • the surface of the microarray is divided into quadrants, each quadrant having a different probe molecule sequences.
  • all of the probe molecules in any quadrant are substantially similar in sequence (such as greater than 85% homologous), and preferably each different quadrant contains a different probe molecule sequence or a different quantity of any probe molecule sequence.
  • each quadrant may have more than one probe molecule sequence.
  • the microarrays of the present invention may have varying number of quadrants, or distinct sub-areas of the microarray.
  • the microarrays preferably can include from about 10 to about 10,000 or more quadrants. Each quadrant preferably has a surface area of 1 square centimeter or less.
  • the quadrant density of the microarray, or the number of quadrants per square centimeter of microarray surface area, may vary. Probe densities may be from about 100 copies to about 10,000 copies of a probe molecule per quadrant. Probe densities as high as 400 or more oligonucleotides per cm 2 have been described in U.S.
  • Patent 5,744,305 to Fodor, et al., and probe densities of as high as 1,000 or more nucleotides per cm 2 have been described in U.S. Patent 5,445,934 issued to Fodor, et al., both patents are hereby incorporated by reference in their entirety.
  • Microarrays may be produced by synthesizing polymers thereon as is disclosed in U.S. Patent 5,436,327 to Southern, et al. (arrays with fluorescent nucleotide analogues) or U.S. Patents 5,445,934 and 5,800,992 to issued to Fodor, et al.(single stranded oligonucleotide probe molecules on the microarray surfaces), herein incorporated by reference.
  • probe molecules exceed about 200 molecules, for example, it is preferable to synthesize the probe molecules separately, and then attach them to the substrate.
  • This method is disclosed in U.S. Patent 5,807,525 to Allen, et al., herein incorporated by reference in its entirety.
  • One advantage of the later method of making the microarray is that microarrays may have a higher purity of the desired sequences and, facilitate the production of sequences of any desired length or varying lengths.
  • Beads useful in this invention are any substrates which maximally facilitate the attachment of probe molecules thereto, and minimally interfere with probe/target pairing and further minimally interfere with detection of the label on the probe molecules.
  • beads are comprised of a ferromagnetic metal coated with a non-soluble polymer material, and the polymer has, coated on its surface, the probe molecules.
  • Beads can be produced in any size and are preferably less than 20 ⁇ m in diameter, and more preferably less than 1 O ⁇ in diameter.
  • the beads have probe molecules of the same sequence attached to its surface.
  • the quantity or number of probe molecules attached to the bead are known.
  • each bead has about 100 to about 1,000 or more probe molecules.
  • a variety of beads can be produced and each bead having the same or a different number of probe molecules attached to its surface.
  • each bead may have more than one probe molecule sequence attached thereto or have an unknown quantity of probe molecules.
  • the presence of a target molecule (or the ability of a target molecule to bind a probe molecule) within a sample can be determined by comparing the level at which the label is detected in any quadrant before and after being exposed to the target molecules in the sample. For example, a microarray having labeled probe molecules attached in distinct in quadrants can be evaluated by detecting the level of label expressed within each quadrant a first time. Then, a sample having unlabeled nucleotide target sequences can be added to the microarray and subject to sufficient conditions and time for target molecules to selectively pair with the complimentary labeled probe molecules.
  • the microarray can be evaluated a second " time to detect the level of label expressed within each quadrant after exposure to the sample. Where the level of label expressed during the second evaluation is less that expressed during the first evaluation, at least some amount of a target molecule can be inferred to have been present in the sample, as it is the target/probe pairing which quenches the label from being detected. Further, the amount of quenching is proportionate to the amount of target molecule within the volume of the sample.
  • any quadrant where the amount of probe molecule contained in any quadrant is known, and where the label is substantially undetectable, or detectable at baseline levels after exposure to the sample, one may infer that the sample had at least the same number of target molecules present as probe molecules on the quadrant, where pairing occurs at a 1 : 1 ratio of probe molecules to target molecules.
  • differential gene expression profiles can be analyzed.
  • the mRNA profile or protein profile of a native cell can be compared with cells which are exposed to a treatment, for example. It is known that the expression profile for mRNA or protein or binding ability between a target and probe molecule may be radically changed due to exposure to a treatment, however, the individual molecules that are effected and the degree to which they are effected is unknown.
  • a microarray using the labeled probe molecules of the present invention can be utilized to determine the changes in the expression profile or binding of several target molecules in a particular cell sample. Those skilled in the art will recognize a wide range of different uses for the microarrays of the present invention.
  • the arrays can be put to a variety of uses including detecting the presence of particular sequences in a given sample, and further determining differences and similarities between the probe sequences on the array and target sequences in the liquid sample, as described in U.S. Patent 5,925,525 to Fodor, et al., herein incorporated by reference.
  • the number of target sequences within a cellular sample can be quantified.
  • beads are produced having a known number of probe molecules attached thereto.
  • the amount of marker detected on the probe molecules of a first bead for example fluorescence, is measured a first time.
  • the first bead is then incubated with a sample having target molecules under time and conditions sufficient to maximize the formation of complimentary probe/target pairs.
  • the bead is then removed from the sample, using magnetic energy when the beads include a ferromagnetic core, for example.
  • the amount of marker detected on the first bead is measured a second time.
  • the first bead is discarded and a second bead is incubated with the sample having the remainder of the target molecules.
  • the second bead is discarded and the process is repeated using subsequent beads, which are incubated with the cellular sample such that substantially all of the target molecules are removed from the sample and paired onto the probe molecules of the beads.
  • individual beads are then sequentially added to the cellular sample until the cellular sample no longer quenches the fluorescence of the beads being added.
  • the number of probe molecules on each bead As the number of probe molecules on each bead are known, it is possible to calculate the number of target molecules which were present in the sample per volume which paired with the probe molecules and thereby, quenched the label signal. Further, where the number of target molecules present in a native cellular sample is quantified and the number of target molecules present in an experimental (in vitro or in vivo exposed to a treatment, for example) sample is quantified, the difference between these two numbers is a quantification of the effect of exposing a cell or tissue to the selected treatment conditions.

Abstract

La présente invention concerne un système de dosage utilisant des molécules sondes marquées pour identifier et quantifier des molécules cibles dans un échantillon. Là où les molécules sondes marquées sont présentes sur un substrat tel qu'une micro-matrice, l'identification de molécules différentes et multiples peut être exécutée simultanément. Dans une variante, un nombre connu de molécules de type sondes peuvent être présentes sur un substrat, une molécule à cible unique pouvant alors être quantifiée dans un échantillon. Les molécules sondes marquées préférées comprennent des analogues de nucléotides simple brin fluorescents dont la fluorescence est inhibée par l'appariement avec une séquence cible nucléotidique homologue.
PCT/US2000/032303 1999-11-24 2000-11-22 Matrices polymeres et procedes d'utilisation de molecules de sondes marquees pour identifier et quantifier l'expression des molecules cibles WO2001038585A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18006/01A AU1800601A (en) 1999-11-24 2000-11-22 Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16742199P 1999-11-24 1999-11-24
US60/167,421 1999-11-24
US09/721,550 2000-11-22
US09/721,550 US6811973B1 (en) 1999-11-24 2000-11-23 Methods of using labeled probe molecules to quantify target molecules

Publications (2)

Publication Number Publication Date
WO2001038585A2 true WO2001038585A2 (fr) 2001-05-31
WO2001038585A3 WO2001038585A3 (fr) 2001-12-20

Family

ID=26863154

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/032303 WO2001038585A2 (fr) 1999-11-24 2000-11-22 Matrices polymeres et procedes d'utilisation de molecules de sondes marquees pour identifier et quantifier l'expression des molecules cibles

Country Status (2)

Country Link
US (2) US6811973B1 (fr)
WO (1) WO2001038585A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063282A2 (fr) * 2000-02-23 2001-08-30 Universite Joseph Fourier De Grenoble Analyse de cibles biologiques utilisant une biopuce comportant un marqueur fluorescent
US20090170075A1 (en) * 2004-05-07 2009-07-02 Gyorgy Petrovics Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425138D0 (en) 1994-12-12 1995-02-08 Dynal As Isolation of nucleic acid
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP2005538929A (ja) 2002-01-16 2005-12-22 ダイナル バイオテック エイエスエイ 単一サンプルからの核酸及びタンパク質の単離方法
GB0229287D0 (en) * 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
EP1761645A4 (fr) * 2004-06-10 2008-12-31 Agency Science Tech & Res Amorces de diagnostic et procede de detection des sous-types h5 et h5n1 du virus de la grippe aviaire
US7645575B2 (en) 2004-09-08 2010-01-12 Xdx, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
US7851152B2 (en) * 2004-09-25 2010-12-14 Yaodong Chen Fluorescent base analogues' usage in the characterization of nucleic acid molecules and their interactions
US7993832B2 (en) 2006-08-14 2011-08-09 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
WO2008140484A2 (fr) 2006-11-09 2008-11-20 Xdx, Inc. Procédés pour diagnostiquer et surveiller l'état d'un lupus érythémateux systémique
US10533215B2 (en) 2008-11-24 2020-01-14 Sequenom, Inc. Nucleic acid quantification products and processes
EP2820157B1 (fr) 2012-03-02 2019-05-01 Winthrop-University Hospital Procédé pour l'utilisation d'une détection par pcr à l'aide d'une sonde pour mesurer les niveaux d'adn en circulation provenant de cellules bêta déméthylées, comme mesure de la perte de cellules bêta en cas de diabète

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861247A (en) * 1996-01-26 1999-01-19 University Of Chicago Rapid method to detect duplex formation in sequencing by hybridization methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5512439A (en) * 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5925525A (en) 1989-06-07 1999-07-20 Affymetrix, Inc. Method of identifying nucleotide differences
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DE69333073T2 (de) 1992-02-12 2004-04-15 Chromagen, Inc., San Diego Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen
US5652099A (en) * 1992-02-12 1997-07-29 Conrad; Michael J. Probes comprising fluorescent nucleosides and uses thereof
SE501010C2 (sv) 1993-03-05 1994-10-17 Moelnlycke Ab Absorberande alster
US6156501A (en) * 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5753516A (en) * 1995-02-03 1998-05-19 Heagy; Wyrta E. Screening method for ligands of the EBI-1 receptor
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
WO1996034983A1 (fr) 1995-05-05 1996-11-07 The Perkin-Elmer Corporation Procedes et reactifs pour combiner une amplification par reaction en chaine de la polymerase et une technique de sondage par hybridation
US5807525A (en) 1995-08-17 1998-09-15 Hybridon, Inc. Apparatus and process for multi stage solid phase synthesis of long chained organic molecules
US6001571A (en) * 1995-11-30 1999-12-14 Mandecki; Wlodek Multiplex assay for nucleic acids employing transponders
US5776711A (en) * 1996-11-12 1998-07-07 The Regents Of The University Of California Simultaneous human ABO and RH(D) blood typing or antibody screening by flow cytometry
WO1998026093A2 (fr) * 1996-12-13 1998-06-18 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formation en epingle a cheveux d'analogue de nucleotides fluorescents pour la detection de l'hybridation d'acides nucleiques
US6100030A (en) * 1997-01-10 2000-08-08 Pioneer Hi-Bred International, Inc. Use of selective DNA fragment amplification products for hybridization-based genetic fingerprinting, marker assisted selection, and high-throughput screening
US5846729A (en) * 1997-02-27 1998-12-08 Lorne Park Research, Inc. Assaying nucleotides in solution using a fluorescent intensity quenching effect
US6187530B1 (en) * 1997-10-03 2001-02-13 Monterey Bay Aquarium Research Institute Aquatic autosampler device
AU2965500A (en) 1999-01-15 2000-08-01 Gene Logic, Inc. Immobilized nucleic acid hybridization reagent and method
DE60045059D1 (de) 1999-04-20 2010-11-18 Nat Inst Of Advanced Ind Scien Verfahren und Sonden zur Bestimmung der Konzentration von Nukleinsäure-Molekülen und Verfahren zur Analyse der gewonnenen Daten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861247A (en) * 1996-01-26 1999-01-19 University Of Chicago Rapid method to detect duplex formation in sequencing by hybridization methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALLEN ET AL.: "Targeted base stacking disruption by the EcoRI DNA methyltransferase" BIOCHEMISTRY, vol. 35, no. 47, 26 November 1996 (1996-11-26), pages 14757-14762, XP002170384 cited in the application *
YGUERABIDE J ET AL: "PYRENE-LABELED DNA PROBES FOR HOMOGENEOUS DETECTION OF COMPLEMENTARY DNA SEQUENCES: POLY(C) MODEL SYSTEM" ANALYTICAL BIOCHEMISTRY,US,ACADEMIC PRESS, SAN DIEGO, CA, vol. 241, no. 2, 15 October 1996 (1996-10-15), pages 238-247, XP000642798 ISSN: 0003-2697 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001063282A2 (fr) * 2000-02-23 2001-08-30 Universite Joseph Fourier De Grenoble Analyse de cibles biologiques utilisant une biopuce comportant un marqueur fluorescent
WO2001063282A3 (fr) * 2000-02-23 2002-04-04 Univ Joseph Fourier De Grenobl Analyse de cibles biologiques utilisant une biopuce comportant un marqueur fluorescent
US6861515B2 (en) 2000-02-23 2005-03-01 Commissariat A L'energie Atomique Analysis of biological targets using a biochip comprising a fluorescent marker
US20090170075A1 (en) * 2004-05-07 2009-07-02 Gyorgy Petrovics Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
US10066268B2 (en) * 2004-05-07 2018-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer
US11236395B2 (en) 2004-05-07 2022-02-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the ERG gene, alone or in combination with other over or under expressed genes in prostate cancer

Also Published As

Publication number Publication date
WO2001038585A3 (fr) 2001-12-20
US6811973B1 (en) 2004-11-02
US20040203050A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
US6811973B1 (en) Methods of using labeled probe molecules to quantify target molecules
US6548257B2 (en) Methods of identifying nucleic acid probes to quantify the expression of a target nucleic acid
US6582908B2 (en) Oligonucleotides
EP1040204B1 (fr) Exploitation de genomes pour la recherche de nouveaux medicaments
EP1319179B1 (fr) Procedes de detection et de dosage de sequences nucleotidiques
US7552013B2 (en) Ratio-based oligonucleotide probe selection
CA2296782A1 (fr) Genes en aval du suppresseur de tumeurs wt1
Lennon High-throughput gene expression analysis for drug discovery
US20090325813A1 (en) Methods and kits for quantitative oligonucleotide analysis
US6316608B1 (en) Combined polynucleotide sequence as discrete assay endpoints
US6448013B1 (en) Duplex probes for hybridization reactions
US6423535B1 (en) Normalization control for hybridization reactions
JP2002505846A (ja) シグナル増幅およびプロセッシングのための多重逐次的ポリヌクレオチド置換反応
Wang et al. Polyacrylamide gel film immobilized molecular beacon array for single nucleotide mismatch detection
JP2005501237A (ja) ３標識マイクロアレイのための方法および装置
US20060003360A1 (en) Method for analyzing variation of nucleic acid and method for analyzing gene expression
EP1261617B1 (fr) Methode d'essai et de detection sur un micro-reseau
EP1418244A1 (fr) Exploitation de la génomique pour identifier des médicaments nouveaux
WO2000029619A2 (fr) Dispositif analytique a plusieurs elements, destine a l'essai de sequences d'acides nucleiques, et utilisations associees
JP2002330767A (ja) 核酸固定化アレイ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP